📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial (2020)

First Author: Andrew R. Pettitt

Attributed to: MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3324/haematol.2019.230805

PubMed Identifier: 32054653

Publication URI: http://europepmc.org/abstract/MED/32054653

Type: Journal Article/Review

Parent Publication: Haematologica

Issue: 12

ISSN: 0390-6078